Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers

[1]  H. Rasmussen,et al.  The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios , 2019, Basic & clinical pharmacology & toxicology.

[2]  Sudha R. Raman,et al.  Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. , 2018, The lancet. Psychiatry.

[3]  Matthias J. Müller,et al.  TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians* , 2018, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[4]  O. Beck,et al.  A liquid chromatography and tandem mass spectrometry method to determine 28 non‐volatile drugs of abuse in exhaled breath , 2018, Journal of pharmaceutical and biomedical analysis.

[5]  K Domschke,et al.  Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 , 2017, Pharmacopsychiatry.

[6]  P. Gustafsson,et al.  Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage , 2016, European Journal of Drug Metabolism and Pharmacokinetics.

[7]  E. Molden,et al.  Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype , 2016, Therapeutic drug monitoring.

[8]  T. Banaschewski,et al.  An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder , 2014, Expert opinion on drug metabolism & toxicology.

[9]  R. Malmström,et al.  Therapeutic drug monitoring for tomorrow , 2013, European Journal of Clinical Pharmacology.

[10]  Olof Beck,et al.  Detection of drugs of abuse in exhaled breath using a device for rapid collection: comparison with plasma, urine and self-reporting in 47 drug users , 2013, Journal of breath research.

[11]  J. V. van Gerven,et al.  Determination of methylphenidate in plasma and saliva by liquid chromatography/tandem mass spectrometry. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  A. Straughn,et al.  Differential Influences of Ethanol on Early Exposure to Racemic Methylphenidate Compared with Dexmethylphenidate in Humans , 2013, Drug Metabolism and Disposition.

[13]  H. Rasmussen,et al.  Enantioselective determination of methylphenidate and ritalinic acid in whole blood from forensic cases using automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. , 2012, Journal of analytical toxicology.

[14]  M. Josefsson,et al.  Determination of methylphenidate and ritalinic acid in blood, plasma and oral fluid from adolescents and adults using protein precipitation and liquid chromatography tandem mass spectrometry--a method applied on clinical and forensic investigations. , 2011, Journal of pharmaceutical and biomedical analysis.

[15]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[16]  J. Franck,et al.  Method for determination of methadone in exhaled breath collected from subjects undergoing methadone maintenance treatment. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[17]  M. Farré,et al.  Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. , 2010, Clinical chemistry.

[18]  S. Bálint,et al.  Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis , 2009, British Journal of Psychiatry.

[19]  J. Lausmaa,et al.  Airway monitoring by collection and mass spectrometric analysis of exhaled particles. , 2009, Analytical chemistry.

[20]  E. Gallardo,et al.  The role of alternative specimens in toxicological analysis. , 2008, Biomedical chromatography : BMC.

[21]  Julie A. Johnson,et al.  Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. , 2008, American journal of human genetics.

[22]  J. Markowitz,et al.  Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? , 2008, Journal of clinical psychopharmacology.

[23]  B. Horta,et al.  The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.

[24]  Carol A. Perlman,et al.  Medication Adherence in Psychopharmacologically Treated Adults With ADHD , 2007, Journal of attention disorders.

[25]  S. Pliszka,et al.  Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder: Efficacy, Safety and Mechanisms of Action , 2007, Neuropsychology Review.

[26]  Olaf H Drummer,et al.  Drug testing in oral fluid. , 2006, The Clinical biochemist. Reviews.

[27]  D. Murry,et al.  Methylphenidate Is Stereoselectively Hydrolyzed by Human Carboxylesterase CES1A1 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[28]  A. Straughn,et al.  Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations , 2003, Pharmacotherapy.

[29]  A. Avenoso,et al.  Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone , 1999, Psychopharmacology.

[30]  D. Parmelee,et al.  Population Pharmacokinetics of Methylphenidate in Children with Attention‐Deficit Hyperactivity Disorder , 1999, Journal of clinical pharmacology.

[31]  G. Breese,et al.  Pharmacology of the enantiomers of threo-methylphenidate. , 1987, The Journal of pharmacology and experimental therapeutics.

[32]  J. Perel,et al.  Metabolism and disposition of methylphenidate-14C: studies in man and animals. , 1974, The Journal of pharmacology and experimental therapeutics.

[33]  J. Franck,et al.  Drug abuse screening with exhaled breath and oral fluid in adults with substance use disorder. , 2019, Drug testing and analysis.

[34]  O. Beck,et al.  Clinical trial of a new technique for drugs of abuse testing: a new possible sampling technique. , 2015, Journal of substance abuse treatment.

[35]  D. Heal,et al.  Methylphenidate and its Isomers , 2006, CNS drugs.

[36]  K. Midha,et al.  Enantioselective Pharmacokinetics of dl-threo-Methylphenidate in Humans , 2004, Pharmaceutical Research.

[37]  D. Abernethy,et al.  Pharmacokinetics and Clinical Effectiveness of Methylphenidate , 1999, Clinical pharmacokinetics.